ENGNW · enGene Therapeutics Inc. · Fails to Deliver
$0.18
At close · Oct 28
Return incl. dividend (before tax)
Going-concern doubt
— cleared Jun 15, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities as of April 30, 2026 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.”View the 10-Q filed Jun 15, 2026
Market Cap
$103.88M
Shares
67.02M
Volume · Oct 28
2311
Avg daily vol (3M)
13.46K
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
No Fails to Deliver Data
No fails-to-deliver data is available for this listed security yet.